Lupin to Sell Generic Version of Merck's Bridion in U.S. After FDA Approval
By Anvee Bhutani
Lupin Ltd. said it launched a generic version in the U.S. of a Merck & Co. injection which reverses the effects of certain muscle relaxants after receiving approval from the Food and Drug Administration.
The Mumbai drugmaker on Thursday said the FDA approved its abbreviated new drug application for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials.
Lupin said the product is bioequivalent to Merck's Bridion and is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and children aged 2 years and older undergoing surgery.
The launch comes roughly a week after President Trump said the U.S. would begin imposing tariffs on imported generic pharmaceuticals in August 2028, with the rate rising to 100% initially and 200% a year later, after a two-year transition period intended to encourage drugmakers to move manufacturing to the U.S.
Write to Anvee Bhutani at anvee.bhutani@wsj.com
(END) Dow Jones Newswires
July 30, 2026 13:36 ET (17:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
33 Undervalued Stocks to Buy Before the Market Shifts Again
The Thrilling 37
United States